The de novo lipogenic transcription factor ChREBP has been implicated in various metabolic disorders, including non-alcoholic fatty liver disease and insulin resistance [6, 14, 18, 19, 35–37]. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.